reports hero background
UPDATED: Nov 12, 2025

Stock Analysis

MBX Biosciences
NASDAQ:MBX
$24.97
$0.06 |0.24%
Day Range:
$24.34 - $25.66
Market Cap:
1.13B
P/E Ratio:
3.2477
Avg Value:
$15.64
Year Range:
$4.81 - $26.47
1
General Information
MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders.

The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291.

2
MBX Biosciences (MBX) Stock Graph
3
How We Grade MBX Biosciences (MBX)

We grade stocks based on past performance, their future growth potential, intrinsic value, dividend history, and overall financial health.

The chart below shows how we grade MBX Biosciences (MBX) across the board compared to its closest peers.

4
Benzinga Edge Rankings

Benzinga Edge stock rankings give you four critical scores to help you identify the strongest and weakest stocks to buy and sell.

Momentum measures a stock's relative strength based on its price movement patterns and volatility over multiple timeframes, ranked as a percentile against other stocks.

Stock Score Locked: Want to See it?
Benzinga Rankings give you vital metrics on any stock – anytime.
5
Peer Ratings

See how MBX Biosciences compares to its peers in these key performance metrics from Benzinga Rankings.

Top Peers
Value
Quality
Growth
Momentum
Short
Medium
Long
OCSOculis Holding
0
0
0
70.88
ELVNEnliven Therapeutics
0
0
0
19.16
NKTRNektar Therapeutics
0
0
0
98.87
MNMDMind Medicine
0
0
0
91.27
Short: price trend over the last couple of months
Medium: price trend over the last couple of quarters
Long: price trend over the past year
Stock Score Locked: Want to See it?
Benzinga Rankings give you vital metrics on any stock – anytime.
6
Future Growth
Our estimate of future price growth is based on an aggregation of 4 analyst ratings over the past 3 months and their 12-month price targets.

Below, you can see that analysts are estimating a 12-month price target range of $36.00 - $84.00 with an average of $63.83

153.31%
Expected movement for MBX Biosciences (MBX) over the next 12 months
Based on these rankings

Recent Ratings for MBX Biosciences (MBX)

Guggenheim
Date:
Nov 10, 2025
Action:
Maintains
Prev. Target:
$84.00
New Target:
$77.00
Mizuho
Date:
Sep 24, 2025
Action:
Maintains
Prev. Target:
$38.00
New Target:
$56.00
Oppenheimer
Date:
Sep 23, 2025
Action:
Maintains
Prev. Target:
$38.00
New Target:
$80.00
Guggenheim
Date:
Sep 23, 2025
Action:
Maintains
Prev. Target:
$44.00
New Target:
$84.00
7
Past Performance
How has MBX Biosciences (MBX) performed over the past 5 years?

The two main factors that we consider when analyzing past performance is overall return and volatility

Using these two metrics, we can determine if this stock gave its investors enough return for the risk that they took on by owning it. This is measured by the sharpe ratio, which has been used as a primary measure of risk/reward trade-off for almost 60 years.

This ratio can be interpreted as the amount of return an investor has received for the amount of risk that they took on by owning the stock over that timeframe.

MBX Biosciences (MBX) sharpe ratio over the past 5 years is -0.0159 which is considered to be above average compared to the peer average of -0.1257